Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.
Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.
Has no medicine on sale, so it funds studies with money raised from investors. It holds the rights outside China to drugs developed by a Chinese partner, under licence terms that normally include milestone and royalty payments, and would earn from sales only after regulators approve a product.
Moat: narrow (IP / patents, regulatory licence). Backed by major biotech investors with licensed clinical-stage assets in the crowded obesity/GLP-1 race.
Headquarters: Boston, Massachusetts, US · Founded: 2024 · Employees: 145
Size Kailera Therapeutics (KLRA) is a United States Health Care company (Biotechnology) with a market value of $1.53B, the 1961st largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.79 on 18 Nov 2026.
Performance Over six months the shares fell 41.3%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Capital Return on invested capital runs 96.1 points below its cost of capital (6.6% WACC).
Short interest Short interest is 6.3% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$310,000 | -$53,000 |
| EBITDA | n/a | -$158M | -$16.3M |
| Net income | n/a | -$149M | -$220M |
| Free cash flow | n/a | -$122M | -$124M |
| Capital expenditure | n/a | $2.09M | $262,000 |
| Total debt | $9.97M | $10.8M | $509,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kailera Therapeutics KLRA | $1.53B | -41% | n/a | n/a | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Viking Therapeutics VKTX | $3.34B | -9% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KLRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.5% | -12.9% | 8th highest of 21 |
| 6-month return | -41.3% | -6.9% | 3rd lowest of 20 |
| Distance from 52-week high | -58.2% | -44.5% | 5th lowest of 21 |
| ROIC minus cost of capital | -96.1 pp | -6.4 pp | lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |